

December 10, 2018

Company name: RIBOMIC Inc.
Representative: Yoshikazu Nakamura, President and CEO
Stock code: 4591
Listing: Tokyo Stock Exchange, Mothers Market
Contact: Emiko Nakamura, Board Director,
Corporate Officer, Corporate Planning
Department

THE PRITZKER NEUROPSYCHIATRIC DISORDERS RESEARCH CONSORTIUM SIGNS A MATERIAL TRANSFER AGREEMENT WITH RIBOMIC INC.

Tokyo, Japan. 2018 –

RIBOMIC Inc. (the “Company” or RIBOMIC) is pleased to announce that it has executed a Material Transfer Agreement (MTA) with the University of Michigan, a member of The Pritzker Neuropsychiatric Disorders Research Consortium (the “Pritzker Consortium”). Under the MTA, RIBOMIC and the Pritzker Consortium will work together to test the effects of RIBOMIC’s aptamers in different in vitro and in vivo models of psychiatric disorders.

“RIBOMIC has a deep expertise in developing therapeutic aptamers to FGF-family proteins. In fact, RIBOMIC’s anti-FGF2 aptamer, named RBM-007, has entered phase I/IIa clinical trials in the United States for age-related macular degeneration. The Company believes that this new collaboration between RIBOMIC and the Pritzker Consortium will open a novel approach to aptamer-based therapy for major psychiatric disorders, such as major depressive disorder, bipolar disorder and schizophrenia” according to Yoshi Nakamura, CEO of RIBOMIC.

Dr. Huda Akil, a Principal Investigator at the Pritzker Consortium said, “We are delighted to have access to the aptamer technology of such an innovative international biotechnology company. This agreement will allow us to test RIBOMIC’s aptamers in animal and in vitro models to determine their functional significance and support the development of new therapeutic candidates to further the translation goals of the Pritzker Consortium”.

About Pritzker Neuropsychiatric Disorders Research Consortium

The Pritzker Consortium seeks to discover the neurobiological and genetic causes of three major psychiatric disorders, Major Depressive Disorder, Bipolar Disorder and Schizophrenia. The Pritzker Consortium also seeks to identify biomarkers and novel targets for drug development. The Consortium conducts studies to identify genetic alterations in brain circuits associated with mood disorders and consists of investigators involved in all aspects of the scientific process from basic to clinical research, from genetics to neuroscience. The multi-dimensional approach is also bi-directional, in that the research process starts with human postmortem brain tissue proceeds to animal models and circles



back to individuals with psychiatric disorders to translate our knowledge into benefits for patients. More information is available at <http://www.pritzkerneuropsych.org/>.

About RIBOMIC Inc.

RIBOMIC Inc. is a bio-venture company centered on drug discovery. The Company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the Company's core drug development platform, can be used for the development of many types of aptamer drugs. RIBOMIC is dedicated to the discovery of drugs that target the broad field of unmet medical needs, which encompasses pain, eye disorders, bone diseases and many other problems. More information is available at <http://www.ribomic.com/en/>.

Contact: <https://www.ribomic.com/en/contact.html>